Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

This study is testing a combination of two drugs — pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy) — given before and after surgery in patients with liver cancer (HCC) that can be surgically removed. The goal is to improve outcomes by treating the cancer from multiple angles. **You may be eligible if...** - You are 18 or older with liver cancer confirmed by imaging or biopsy - Your cancer can be completely removed with surgery - Your liver function is adequate (Child-Pugh A) - You have not received prior systemic treatment or immunotherapy for your liver cancer - Your hepatitis B or C is controlled **You may NOT be eligible if...** - You have liver cancer that has spread outside the liver - You have previously received immune checkpoint therapies (like anti-PD-1 drugs) - You have active autoimmune disease requiring treatment - You have significant heart problems, recent heart attack, or unstable blood pressure - You are pregnant or breastfeeding - You have active HIV infection Talk to your doctor to see if this trial is right for you.